Genelux:1st patient dosed in VIRO-25 trial with Olvi-Vec in NSCLC

Genelux (GNLX) Corporation announced that the first patient has been dosed in the U.S.-based Phase 2 or VIRO-25, trial evaluating systemically delivered Olvi-Vec in patients with recurrent non-small cell lung cancer NSCLC who have failed frontline platinum and immune checkpoint inhibitor ICI therapie”Today’s milestone holds profound significance for patients with recurrent non-small cell lung cancer who face limited therapeutic options,” said Thomas Zindrick, President, CEO and Chairman of Genelux. “This Phase 2 trial, in addition to our ongoing Phase 1b/2 trial evaluating intravenous delivered Olvi-Vec in patients with recurrent small cell lung cancer, co-sponsored with Newsoara Biopharma signifies the key advancement of Olvi-Vec to potentially be an important systemically administered oncolytic virus treatment option, setting the stage for the future of this promising field.” …Olvi-Vec’s previous data suggests a manageable safety profile, and this trial looks to further confirm the hypothesis that Olvi-Vec may resensitize to platinum in multiple tumor types. Genelux expects interim data readout in mid-2025.